Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell GENinCode (GENI) by Steve Moore in ShareProphets
- Buy Wynnstay Group (WYN) by Hot Stock Rockets in ShareProphets
- Avoid Victorian Plumbing Group (VIC) by Steve Moore in ShareProphets
- Overweight AstraZeneca (AZN) by JP Morgan
- Outperform Smith & Nephew (SN.) by RBC Capital
- Outperform Paragon Banking Group (PAG) by RBC Capital
- Sell Ondo Insurtech (ONDO) by Steve Moore in ShareProphets
- Neutral Vodafone Group (VOD) by Bank of America
- Neutral BT Group (BT.A) by Bank of America
- Overweight SSP Group (SSPG) by Barclays
- Overweight Watches of Switzerland Group (WOSG) by Barclays
- Hold Victorian Plumbing Group (VIC) by Deutsche Bank
- Buy Lloyds Banking Group (LLOY) by Goldman Sachs
- Neutral Land Securities Group (LAND) by Goldman Sachs
- Neutral Hammerson (HMSO) by Goldman Sachs
- Buy Derwent London (DLN) by Goldman Sachs
- Buy British Land Company (BLND) by Goldman Sachs
- Neutral Great Portland Estates (GPE) by Goldman Sachs
- Buy B&M European Value Retail S.A. (DI) (BME) by Berenberg
- Outperform Mitie Group (MTO) by RBC Capital
AstraZeneca (AZN) Share Price
Health Care Sector
NOTE: This is based on 1,242 open tips for AstraZeneca (AZN)
| Latest Bid : 13,514.00p | Latest Ask : 13,518.00p |
| High Today : 13,662.00p | Low Today : 13,511.12p |
| This Years High : 14,148.00p | This Years Low : 9,667.00p |
| Volume : 992,260 | MKT Cap : £209467M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
AstraZeneca (AZN) Overview
A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.AstraZeneca (AZN) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Overweight | JP Morgan | Premium Only | 2025-12-04 12:16:00 04/12/2025 | -0.56% |
| Buy | Simon Watkins | Premium Only | 2025-11-17 09:15:00 17/11/2025 | -0.12% |
| Outperform | Bernstein | Premium Only | 2025-11-14 06:18:00 14/11/2025 | 0.37% |
| Overweight | JP Morgan | Premium Only | 2025-11-10 18:00:00 10/11/2025 | 0.85% |
| Hold | DZ Bank | Premium Only | 2025-11-10 13:02:00 10/11/2025 | 3.46% |
AstraZeneca (AZN) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 13,514.00p | Latest Ask : 13,518.00p |
| High Today : 13,662.00p | Low Today : 13,511.12p |
| This Years High : 14,148.00p | This Years Low : 9,667.00p |
| Volume : 992,260 | MKT Cap : £209467M |
AstraZeneca Overview
A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest AstraZeneca Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Overweight | JP Morgan | Premium Only | 2025-12-04 12:16:00 04/12/2025 | -0.56% |
| Buy | Simon Watkins | Premium Only | 2025-11-17 09:15:00 17/11/2025 | -0.12% |
| Outperform | Bernstein | Premium Only | 2025-11-14 06:18:00 14/11/2025 | 0.37% |
| Overweight | JP Morgan | Premium Only | 2025-11-10 18:00:00 10/11/2025 | 0.85% |
| Hold | DZ Bank | Premium Only | 2025-11-10 13:02:00 10/11/2025 | 3.46% |